Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
27.45
+0.40 (1.48%)
At close: Apr 28, 2026, 4:00 PM EDT
27.99
+0.54 (1.97%)
After-hours: Apr 28, 2026, 5:51 PM EDT
Company Description
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases.
The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University.
The company was founded in 2018 and is headquartered in New York, New York.
Neurogene Inc.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 131 |
| CEO | Rachel McMinn |
Contact Details
Address: 535 W 24th Street, 5th Floor New York, New York 10011 United States | |
| Phone | 855 508 3568 |
| Website | neurogene.com |
Stock Details
| Ticker Symbol | NGNE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1404644 |
| CUSIP Number | 64135M105 |
| ISIN Number | US64135M1053 |
| Employer ID | 98-0542593 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Rachel L. McMinn Ph.D. | Founder, Executive Chair and Chief Executive Officer |
| Christine Mikail Cvijic J.D. | President and Chief Financial Officer |
| Dr. Julie Jordan M.D. | Chief Medical Officer |
| Dr. Stuart Cobb Ph.D. | Chief Scientific Officer |
| Donna M. Cochener-Metcalfe J.D., L.L.M. | Senior Vice President, General Counsel and Corporate Secretary |
| Ricardo Jimenez | Senior Vice President of Technical Operations |
| Arvind Sreedharan | Senior Vice President of Business Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 20, 2026 | 8-K | Current Report |
| Apr 16, 2026 | ARS | Filing |
| Apr 16, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 16, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 24, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 24, 2026 | 10-K | Annual Report |
| Mar 24, 2026 | 8-K | Current Report |
| Mar 13, 2026 | 144 | Filing |
| Feb 27, 2026 | 144 | Filing |
| Feb 26, 2026 | 8-K | Current Report |